23
Aug
Aug
BPC-157 is not an FDA-approved drug. What that means, the 2023-2026 compounding timeline, and how “approved,” “scheduled,” and “compounding list” differ.
23
Aug
Aug
A plain answer to a question most sellers avoid: no Phase II or III human trial of BPC-157 has ever been published. Here is what the human record actually holds.
FDA letter 694608-12102024 cited Xcel Research LLC’s long GLP-1-class product list. Why catalog breadth is not verification — and what to check instead.
SwissChems was named in FDA’s December 10, 2024 warning-letter batch. How to read the letter itself — and how to vet a verification-first alternative.
FDA letter 695607-12102024 cited Summit Research Peptides’ catalog and a company Facebook post. How to audit a successor vendor’s entire footprint.
FDA letter 695156-12102024 told Prime Peptides an RUO disclaimer is no defense. What totality of evidence means and how to audit a vendor in five minutes.
Dated timeline of US research-peptide enforcement, December 2024 to July 2026: FDA warning letters, the Amino Asylum raid, Paradigm pleas and sentencing.
A dated record of peptide vendor closures 2025-2026: Peptide Sciences, Amino Asylum, Paradigm Peptides, and two FDA warning-letter batches, with links.
Peptide Sciences shut down March 6, 2026, and its notice calls further brand sales fraudulent. Dated facts, clone-site red flags, successor checklist.
Peptide Sciences closed March 6, 2026. A verification-first framework for choosing an alternative: third-party HPLC and MS testing, COAs, cited evidence.